FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885511257> ?p ?o ?g. }

• W2885511257 endingPage "1550" @default.
• W2885511257 startingPage "1543" @default.
• W2885511257 abstract "Purpose To compare single-fraction 153Gd-based rotating shield brachytherapy (RSBT) for prostate cancer with conventional 192Ir-based high-dose-rate brachytherapy (HDR-BT) in a planning study that radiobiologically accounts for dose rate and relative biological effectiveness. RSBT was used for planning target volume (PTV) dose escalation without increasing urethral dose for monotherapy, or for urethral sparing without decreasing PTV dose as a boost to external beam radiation therapy. Methods and Materials Twenty-six patients were studied. PTV doses were expressed as equivalent dose delivered in 2 Gy fractions (EQD2), accounting for relative biological effectiveness (1.00 for 192Ir and 1.15 for 153Gd), dose protraction (114-minute repair half-time), and tumor dose response (α/β of 3.41 Gy). HDR-BT dose was prescribed such that 90% of the PTV received 110% of the prescription dose of 19 Gy for dose escalation and 15 Gy for urethral sparing, corresponding to EQD290% values (minimum EQD2 to the hottest 90% of the PTV) of 93.9 GyEQD2 and 60.7 GyEQD2, respectively. Twenty 90.95 GBq 153Gd RSBT sources and one 370 GBq 192Ir HDR-BT source were modeled. Results For dose escalation with fresh sources, RSBT increased PTV EQD290% by 42.5% ± 8.4% (average ± standard deviation) without increasing urethral D10%, with treatment times of 216.8 ± 28.9 minutes versus 15.1 ± 2.1 minutes. After 1 half-life (240.4 days for 153Gd and 73.8 days for 192Ir), EQD290% increased 20.5% ± 9.1%. For urethral sparing with fresh sources, RSBT decreased urethral D10% by 26.0% ± 3.4% without decreasing PTV EQD290%, with treatment times of 133.6 ± 16.5 minutes versus 12.0 ± 1.7 minutes. After 1 half-life, urethral D10% decreased 20.2% ± 4.8%. Conclusions RSBT can increase PTV EQD90% or decrease urethral D10% relative to HDR-BT at the cost of increased treatment time. Source aging reduces RSBT benefit, but RSBT remains theoretically superior to HDR-BT by >20% after 1 half-life has elapsed. To compare single-fraction 153Gd-based rotating shield brachytherapy (RSBT) for prostate cancer with conventional 192Ir-based high-dose-rate brachytherapy (HDR-BT) in a planning study that radiobiologically accounts for dose rate and relative biological effectiveness. RSBT was used for planning target volume (PTV) dose escalation without increasing urethral dose for monotherapy, or for urethral sparing without decreasing PTV dose as a boost to external beam radiation therapy. Twenty-six patients were studied. PTV doses were expressed as equivalent dose delivered in 2 Gy fractions (EQD2), accounting for relative biological effectiveness (1.00 for 192Ir and 1.15 for 153Gd), dose protraction (114-minute repair half-time), and tumor dose response (α/β of 3.41 Gy). HDR-BT dose was prescribed such that 90% of the PTV received 110% of the prescription dose of 19 Gy for dose escalation and 15 Gy for urethral sparing, corresponding to EQD290% values (minimum EQD2 to the hottest 90% of the PTV) of 93.9 GyEQD2 and 60.7 GyEQD2, respectively. Twenty 90.95 GBq 153Gd RSBT sources and one 370 GBq 192Ir HDR-BT source were modeled. For dose escalation with fresh sources, RSBT increased PTV EQD290% by 42.5% ± 8.4% (average ± standard deviation) without increasing urethral D10%, with treatment times of 216.8 ± 28.9 minutes versus 15.1 ± 2.1 minutes. After 1 half-life (240.4 days for 153Gd and 73.8 days for 192Ir), EQD290% increased 20.5% ± 9.1%. For urethral sparing with fresh sources, RSBT decreased urethral D10% by 26.0% ± 3.4% without decreasing PTV EQD290%, with treatment times of 133.6 ± 16.5 minutes versus 12.0 ± 1.7 minutes. After 1 half-life, urethral D10% decreased 20.2% ± 4.8%. RSBT can increase PTV EQD90% or decrease urethral D10% relative to HDR-BT at the cost of increased treatment time. Source aging reduces RSBT benefit, but RSBT remains theoretically superior to HDR-BT by >20% after 1 half-life has elapsed." @default.
• W2885511257 created "2018-08-22" @default.
• W2885511257 creator A5016958000 @default.
• W2885511257 creator A5021903894 @default.
• W2885511257 creator A5031462011 @default.
• W2885511257 creator A5042571492 @default.
• W2885511257 creator A5044520965 @default.
• W2885511257 creator A5053943952 @default.
• W2885511257 creator A5077618569 @default.
• W2885511257 creator A5077737098 @default.
• W2885511257 creator A5089863285 @default.
• W2885511257 date "2018-12-01" @default.
• W2885511257 modified "2023-10-06" @default.
• W2885511257 title "Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing" @default.
• W2885511257 cites W1489963450 @default.
• W2885511257 cites W1571792083 @default.
• W2885511257 cites W1605082243 @default.
• W2885511257 cites W1966397853 @default.
• W2885511257 cites W1974135738 @default.
• W2885511257 cites W1979538859 @default.
• W2885511257 cites W1990510898 @default.
• W2885511257 cites W1995480733 @default.
• W2885511257 cites W2008291645 @default.
• W2885511257 cites W2014233043 @default.
• W2885511257 cites W2022519467 @default.
• W2885511257 cites W2034161051 @default.
• W2885511257 cites W2039824162 @default.
• W2885511257 cites W2040935952 @default.
• W2885511257 cites W2041203398 @default.
• W2885511257 cites W2045136752 @default.
• W2885511257 cites W2054899405 @default.
• W2885511257 cites W2077234964 @default.
• W2885511257 cites W2078790610 @default.
• W2885511257 cites W2086604707 @default.
• W2885511257 cites W2094442174 @default.
• W2885511257 cites W2135836817 @default.
• W2885511257 cites W2141952239 @default.
• W2885511257 cites W2155624513 @default.
• W2885511257 cites W2158734599 @default.
• W2885511257 cites W2283124353 @default.
• W2885511257 cites W2340856091 @default.
• W2885511257 cites W2548525236 @default.
• W2885511257 cites W2549517959 @default.
• W2885511257 cites W2560206749 @default.
• W2885511257 cites W2569728867 @default.
• W2885511257 cites W2591200989 @default.
• W2885511257 cites W2642983793 @default.
• W2885511257 cites W2682351795 @default.
• W2885511257 cites W2758533018 @default.
• W2885511257 cites W2758930451 @default.
• W2885511257 cites W2759220200 @default.
• W2885511257 cites W2768736160 @default.
• W2885511257 cites W2783123637 @default.
• W2885511257 cites W2905153461 @default.
• W2885511257 doi "https://doi.org/10.1016/j.ijrobp.2018.07.2015" @default.
• W2885511257 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6363898" @default.
• W2885511257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30092333" @default.
• W2885511257 hasPublicationYear "2018" @default.
• W2885511257 type Work @default.
• W2885511257 sameAs 2885511257 @default.
• W2885511257 citedByCount "10" @default.
• W2885511257 countsByYear W28855112572019 @default.
• W2885511257 countsByYear W28855112572020 @default.
• W2885511257 countsByYear W28855112572021 @default.
• W2885511257 countsByYear W28855112572023 @default.
• W2885511257 crossrefType "journal-article" @default.
• W2885511257 hasAuthorship W2885511257A5016958000 @default.
• W2885511257 hasAuthorship W2885511257A5021903894 @default.
• W2885511257 hasAuthorship W2885511257A5031462011 @default.
• W2885511257 hasAuthorship W2885511257A5042571492 @default.
• W2885511257 hasAuthorship W2885511257A5044520965 @default.
• W2885511257 hasAuthorship W2885511257A5053943952 @default.
• W2885511257 hasAuthorship W2885511257A5077618569 @default.
• W2885511257 hasAuthorship W2885511257A5077737098 @default.
• W2885511257 hasAuthorship W2885511257A5089863285 @default.
• W2885511257 hasBestOaLocation W28855112572 @default.
• W2885511257 hasConcept C121608353 @default.
• W2885511257 hasConcept C126322002 @default.
• W2885511257 hasConcept C126894567 @default.
• W2885511257 hasConcept C141071460 @default.
• W2885511257 hasConcept C19527891 @default.
• W2885511257 hasConcept C2777085111 @default.
• W2885511257 hasConcept C2777416452 @default.
• W2885511257 hasConcept C2780192828 @default.
• W2885511257 hasConcept C2989005 @default.
• W2885511257 hasConcept C3017588741 @default.
• W2885511257 hasConcept C509974204 @default.
• W2885511257 hasConcept C71924100 @default.
• W2885511257 hasConceptScore W2885511257C121608353 @default.
• W2885511257 hasConceptScore W2885511257C126322002 @default.
• W2885511257 hasConceptScore W2885511257C126894567 @default.
• W2885511257 hasConceptScore W2885511257C141071460 @default.
• W2885511257 hasConceptScore W2885511257C19527891 @default.
• W2885511257 hasConceptScore W2885511257C2777085111 @default.
• W2885511257 hasConceptScore W2885511257C2777416452 @default.
• W2885511257 hasConceptScore W2885511257C2780192828 @default.
• W2885511257 hasConceptScore W2885511257C2989005 @default.
• W2885511257 hasConceptScore W2885511257C3017588741 @default.

• next